GENOVA, Inc.

Tokyo Stock Exchange 9341.T

GENOVA, Inc. EBITDA for the year ending March 31, 2024: USD 15.96 M

GENOVA, Inc. EBITDA is USD 15.96 M for the year ending March 31, 2024, a 19.57% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • GENOVA, Inc. EBITDA for the year ending March 31, 2023 was USD 13.35 M, a 47.78% change year over year.
  • GENOVA, Inc. EBITDA for the year ending March 31, 2022 was USD 9.03 M, a 21.76% change year over year.
  • GENOVA, Inc. EBITDA for the year ending March 31, 2021 was USD 7.42 M.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
SV Wall Street
Tokyo Stock Exchange: 9341.T

GENOVA, Inc.

CEO Mr. Tomoki Hirase
IPO Date Dec. 23, 2022
Location Japan
Headquarters Shibuya Hikarie
Employees 352
Sector Health Care
Industries
Hospitals & Clinics Medical Instruments Pharmaceuticals Telehealth
Description

GENOVA, Inc. engages in the medical platform and smart clinic businesses in Japan. It offers Medical Doc, a platform that distributes articles for medical institutions, patient experience articles, treatment videos, and medical-related articles. It also provides Smart Clinic, an online medical treatment and consultation service, which offers medical treatment at home or work for users without going to a hospital. In addition, the company offers NOMOCa-Stand, a smart and simple automatic payment and reception machine; NOMOCa-Regi, a self-pay machine dedicated to the clinic; and CLINIC BOT, an AI Chatbot System. The company was founded in 2005 and is headquartered in Tokyo, Japan.

StockViz Staff

February 1, 2025

Any question? Send us an email